Martha Stewart

The Securities and Exchange Commission filed civil insider trading charges against the queen of stylish living related to the sale of ImClone Systems Inc. stock in December 2001. Stewart allegedly sold her ImClone shares the day before the FDA announced it had declined to review ImClone's application for its cancer drug Erbitux; the stock fell 16% in the wake of the announcement. Under the terms of the settlement Stewart will pay $195,000 and cannot serve as the director of a public company for five years. (Aug-07-06) [NEWS 11 ALIVE]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.